This research study is evaluating the combination of drugs, pembrolizumab with chimeric
antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell
lymphoma that has recurred after prior treatment.
The names of the study drugs involved in this study are:
- Pembrolizumab
Standard treatment will include:
- CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel)
- Cyclophosphamide
- Fludarabine